1. [Progress and prospect of clinical application of anti-rabies virus monoclonal antibody preparation].
- Author
-
Lyu XJ, Dong GM, Liu XQ, Liu S, Liu C, Chen QJ, Yin WW, and Wang CL
- Subjects
- Humans, Immunosuppressive Agents, Antibodies, Monoclonal therapeutic use, Antibodies, Viral, Rabies prevention & control, Rabies virus, Rabies Vaccines
- Abstract
Rabies is a severe infectious disease caused by the rabies virus, which seriously damages the central nervous system. Once it occurs, the fatality rate is close to 100%. The World Health Organization's position paper on rabies vaccines recognizes that rabies immunoglobulin (RIG) should be used for post-exposure prophylaxis (PEP) in all category Ⅲ exposure for the first time, as well as in category Ⅱ exposure that suffer from severe immune deficiency, long-term massive use of immunosuppressants, and head and face exposure. The anti-rabies virus monoclonal antibody has high purity and specific activity, can be produced on a sustainable scale, and has no risk of blood source virus contamination. Preclinical pharmacodynamic studies and clinical trial results of the anti-rabies virus monoclonal antibody preparation have confirmed that the preparation has a broad-spectrum neutralization effect on the rabies virus. Additionally, its combined application with the vaccine has little impact on the active immunity of the vaccine. Therefore, the anti-rabies virus monoclonal antibody preparation shows great potential for clinical application in PEP.
- Published
- 2023
- Full Text
- View/download PDF